Skip to main content
SpringerLink
Log in

Calcium Antagonists in the Post-Myocardial Infarction Setting

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

At present, the use of calcium antagonists for the secondary prevention of cardiac events following an acute myocardial infarction (MI) is not recommended. This advice is based on several large mortality studies using short-acting calcium antagonists in the absence of coronary reperfusion therapy. Even in these studies, discrepancies between the different pharmacological classes of calcium antagonists were recognised. When separated from the dihydropyridine calcium antagonists, the rate-lowering calcium antagonists, verapamil and diltiazem, do appear to provide some benefit in reduction of recurrent MI.

Three large trials using verapamil post-MI demonstrated a significant reduction in reinfarction with a favourable trend towards reducing death as well. Similarly, the effects of diltiazem post-MI have been evaluated in 3 large trials. In 2 earlier trials, diltiazem lessened cardiac events in patients with nonQ-wave infarctions and those without pulmonary congestion upon presentation. Overall, there was a significant benefit in lessening reinfarction with no effect on mortality. The recently completed Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Infarction (INTERCEPT) trial found that sustained-release diltiazem given after thrombolytic therapy for acute MI lessened cardiac events by 23% (a nonsignificant difference) without worsening congestive symptoms. Overall, there is adequate data to support the use of heartrate-lowering calcium antagonists for secondary prevention post-MI provided the patient is intolerant of β-blocker therapy. These trials are reviewed in detail, and suggestions for clinical practice are provided in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHAguidelines for the management of acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28 (5): 1328–428

    Article  PubMed  CAS  Google Scholar 

  2. Campbell CA, Kloner RA, Alker KJ, et al. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. J Am Coll Cardiol 1986; 8: 1169–74

    Article  PubMed  CAS  Google Scholar 

  3. Nayler WJ, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine, and propranolol on mitochondial function in the ischemic and reperfused myocardium. Am J Cardiol 1980; 46: 242–8

    Article  PubMed  CAS  Google Scholar 

  4. Rousseau G, St-Jean G, Latour JG, et al. Diltiazem at reperfusion reduces neutrophil accumulation and infarct size in dogs with ischaemic myocardium. Cardiovasc Res 1991; 25: 319–29

    Article  PubMed  CAS  Google Scholar 

  5. Ehring T, Heusch G. Stunned myocardium and the attenuation of stunning by calcium antagonists. Am J Cardiol 1995; 75 Suppl. E: 61–7E

    Article  Google Scholar 

  6. Higginson L, Tang A, Knoll G, et al. Effect of intracoronary diltiazem on infarct size and regional myocardial function in the ischemic reperfused canine heart. J Am Coll Cardiol 1991; 18: 868–75

    Article  PubMed  CAS  Google Scholar 

  7. DeBoer LWV, Strauss HW, Kloner RA, et al. Autoradiographic method for measuring the ischemic myocardium at risk: effects of verapamil on infarct size after experimental coronary artery occlusion. Proc Natl Acad Sci U S A 1980; 77: 6119–23

    Article  PubMed  CAS  Google Scholar 

  8. Lo HM, Kloner RA, Braunwald E. Effect of intracoronary verapamil on infarct size in the ischemic reperfused canine heart: clinical importance of the timing of treatment. Am J Cardiol 1985; 56: 672–7

    Article  PubMed  CAS  Google Scholar 

  9. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, editors. Hypertension: pathology, diagnosis, and management. New York (NY): Raven Press, 1995: 2815–25

    Google Scholar 

  10. Hosie J, Bremner AD, Fell PJ, et al. Side-effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard. J Cardiovasc Pharmacol 1993; 22 Suppl. A: S9–12

    PubMed  Google Scholar 

  11. Wallen NH, Held C, Rehnqvist N, et al. Platelet aggregability in vivo is attenuated by verapamil but not metoprolol in patients with stable angina pectoris. Am J Cardiol 1995; 75: 1–6

    Article  PubMed  CAS  Google Scholar 

  12. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: the TRENT study. BMJ 1986; 293: 1204–8

    Article  PubMed  CAS  Google Scholar 

  13. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354–64

    Google Scholar 

  14. Goldbourt U, Bechar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israeli Nifedipine Trial 2 Study. Arch Intern Med 1993; 153: 345–53

    Article  PubMed  CAS  Google Scholar 

  15. Held P, Yusuf S, Furberg C. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–92

    Article  PubMed  CAS  Google Scholar 

  16. Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516–28

    Google Scholar 

  17. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990; 66: 779–85

    Article  Google Scholar 

  18. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365–9

    Article  PubMed  CAS  Google Scholar 

  19. Crea F, Deanfield J, Crean P, et al. Effects of verapamil in preventing early post-infarction angina and reinfarction. Am J Cardiol 185; 55: 900–4

  20. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997; 79: 738–41

    Article  PubMed  CAS  Google Scholar 

  21. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998; 21: 633–41

    Article  PubMed  CAS  Google Scholar 

  22. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92

    Article  Google Scholar 

  23. Gibson RS, Boden WE, Theroux R, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423–9

    Article  PubMed  CAS  Google Scholar 

  24. Datta P, Stewart DJ, Langer A, et al. Are calcium channel blockers safe post-myocardial infarction? The CAMI experience [abstract]. Circulation 1997; 96: 700

    Article  Google Scholar 

  25. Hager WD, Davis BR, Riba A, et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: the SAVE study experience. Am Heart J 1998; 135: 406–13

    Article  PubMed  CAS  Google Scholar 

  26. Theroux P, Gregoire J, Chin C, et al. Intravenous diltiazem in acute myocardial infarction. J Am Coll Cardiol 1998; 32: 620–8

    Article  PubMed  CAS  Google Scholar 

  27. Sheiban I, Tonni S, Chizzoni A, et al. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther 1997; 11: 5–16

    Article  PubMed  CAS  Google Scholar 

  28. Przyklenk K, Kloner RA. Effect of verapamil on post-ischemic ‘stunned’ myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988; 11: 614–23

    Article  PubMed  CAS  Google Scholar 

  29. Taylor AL, Golino P, Eckels R, et al. Differential enhancement of post-ischemic segmental thickening by diltiazem. J Am Coll Cardiol 1990; 15: 737–47

    Article  PubMed  CAS  Google Scholar 

  30. Przyklenk K, Ghafari GB, Eitzman DT, et al. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of post-ischemic ‘stunned’ myocardium. J Am Coll Cardiol 1989; 13: 1176–83

    Article  PubMed  CAS  Google Scholar 

  31. Boden WE, Scheldewaert R, Walters EG, et al. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Am J Cardiol 1995; 75 (16): 1120–3

    Article  PubMed  CAS  Google Scholar 

  32. Fergusson JL. Meeting highlights: highlights of the 71st Scientific Sessions of the American Heart Association. Circulation 1999; 99: 2487

    Google Scholar 

  33. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996; 17: 43–63

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. North Mississippi Medical Center, Tupelo, Mississippi, USA

    Barry D. Bertolet

Authors
  1. Barry D. Bertolet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barry D. Bertolet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertolet, B.D. Calcium Antagonists in the Post-Myocardial Infarction Setting. Drugs & Aging 15, 461–470 (1999). https://doi.org/10.2165/00002512-199915060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915060-00006

Keywords

Search

Navigation